Terumo Corporation is a Japan-based global medical technology company that develops, manufactures, and supplies devices and systems for vascular intervention, cardiothoracic surgery, transfusion and infusion therapy, and blood and cell management. Serving hospitals, blood centers, and life-science laboratories worldwide, its portfolio includes catheters, stents, guidewires, syringes and needles, infusion devices, perfusion and oxygenation systems, vascular grafts, and platforms for blood component and cell processing.
The company operates through businesses such as Terumo Interventional Systems, Terumo Aortic, Terumo Blood and Cell Technologies (Terumo BCT), and Terumo Medical Corporation in the Americas. Headquartered in Tokyo with manufacturing and R&D across Asia, Europe, and the Americas, Terumo is listed on the Tokyo Stock Exchange. Its technologies support clinical areas including cardiology, endovascular therapy, oncology, critical care, and transfusion medicine.
Also known as Terumo Blood and Cell Technologies, Terumo BCT, Terumo Medical Corporation, Terumo Interventional Systems, Terumo Corporation, and Terumo Aortic.
Effective June 1, 2026, he brings 20+ years at Terumo in sales, strategy and business development, including Chief of Staff experience, to scale commercial growth and NMP adoption.
Effective April 2026 the business segment will be renamed; the disclosure segment name will change starting with consolidated results for fiscal year ending March 2026.
Evaluate a 3-in-1 workflow to stabilize and scale Treg production for TRK-001 Phase 2, cut variability and COGS, shorten cycle time, and enable next-gen engineered Treg INDs.
The FDA's Breakthrough Device Designation accelerates the review of Fenestrated TREO®, a custom stent-graft for complex abdominal aortic aneurysms, offering a tailored, minimally invasive solution.
The Heverlee site earns the Factory of the Future title for 2026–2028, highlighting its focus on innovation, sustainability, and quality in healthcare manufacturing.
Terumo focuses on sustainability, reducing emissions, conserving resources, and improving patient quality of life, achieving top CDP ratings in climate and water security.
All eight Terumo Asia Pacific entities are certified as a Great Place to Work, highlighting their commitment to a supportive workplace culture and enhancing talent attraction and retention.
Appleton's CBC uses new automation to streamline blood processing, cutting manual time by 60% and improving service to hospitals in Wisconsin, Illinois, and Michigan's Upper Peninsula.
